Trametinib

The following clinically significant adverse reactions are described elsewhere in the labeling:

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: The following clinically significant adverse reactions are described elsewhere in the labeling:

Side effects, and when to stop

New Primary Malignancies
Hemorrhage
Colitis and Gastrointestinal Perforation
Venous Thromboembolic Events
Cardiomyopathy
Ocular Toxicities
Interstitial Lung Disease/Pneumonitis
Serious Febrile Reactions
Serious Skin Toxicities
Hyperglycemia
Hemophagocytic Lymphohistiocytosis

There are additional adverse reactions associated with dabrafenib. Refer to the dabrafenib prescribing information for additional information.

Who should not take it

None.

Other medicines and interactions

MEKINIST is indicated for use in combination with dabrafenib. Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Trametinib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/trametinib
APA 7th: sofidex. (2026, August 3). Trametinib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/trametinib
AMA 11th: Trametinib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/trametinib

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.